A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
Phase 3
Completed
- Conditions
- COVID-19
- Interventions
- Other: Placebo controlBiological: Recombinant COVID-19 vaccine (Sf9 cells)
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 39663
- Registration Number
- NCT04904471
- Locations
- ๐ฎ๐ฉ
Puskesmas Ciketingudik, Bekasi, Jiangsu, Indonesia
๐ฎ๐ฉPermata Hospital, Bekasi, Indonesia
๐ฎ๐ฉUniversitas Muhammadiyah Malang Hospital, Malang, Indonesia
ยฉ Copyright 2025. All Rights Reserved by MedPath